Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    imu-131
Previous Study | Return to List | Next Study

A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02795988
Recruitment Status : Recruiting
First Posted : June 10, 2016
Last Update Posted : May 6, 2020
Sponsor:
Information provided by (Responsible Party):
Imugene Limited

Tracking Information
First Submitted Date  ICMJE June 1, 2016
First Posted Date  ICMJE June 10, 2016
Last Update Posted Date May 6, 2020
Actual Study Start Date  ICMJE August 30, 2017
Estimated Primary Completion Date December 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 1, 2019)
  • Safety and tolerability of IMU-131 (Phase 1b) [ Time Frame: Day 0 to Day 56 ]
    The safety and tolerability of IMU-131 will be evaluated by adverse events (AEs) and laboratory measurements.
  • Recommended Phase 2 dose of IMU-131 (Phase 1b) [ Time Frame: Day 0 to Day 56 ]
    The recommended phase 2 dose will be evaluated by safety/tolerability and immunogenicity data for IMU-131 (P467- specific antibodies (IgG) and Her-2- specific antibodies (IgG) titers).
  • Clinical efficacy of IMU-131 (Phase 2) [ Time Frame: Day 0 to Death (Approximately 17.5 months) ]
    To evaluate the clinical efficacy of IMU-131 based on overall survival (OS).
Original Primary Outcome Measures  ICMJE
 (submitted: June 9, 2016)
  • Incidence of treatment-emergent adverse events [ Time Frame: Day 0 to Day 56 ]
    To be evaluated by the number, duration and severity of treatment emergent adverse events (AEs).
  • Recommended Phase 2 Dose (RP2D) [ Time Frame: Day 0 to Day 56 ]
    To be evaluated by safety/tolerability and immunogenicity data for IMU-131 (P467-specific antibodies (IgG) and Her-2- specific antibodies (IgG) titers).
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 1, 2019)
  • Progression Free Survival (Phase 2) [ Time Frame: Day 0 to Progression (approx. 7.5 months) ]
    To evaluate other efficacy measures of IMU-131: progression-free survival (PFS).
  • Time to progression (Phase 2) [ Time Frame: Day 0 to Progression (approx. 7.5 months) ]
    To evaluate other efficacy measures of IMU-131: time to progression (TTP).
  • Disease Control Rate (Phase 2) [ Time Frame: Day 0 to Progression (approx. 7.5 months) ]
    To evaluate other efficacy measures of IMU-131: disease control rate (DCR).
  • Objective Response Rate (Phase 2) [ Time Frame: Day 0 to Progression (approx. 7.5 months) ]
    To evaluate other efficacy measures of IMU-131: objective response rate (ORR).
  • Duration of Objective Response (Phase 2) [ Time Frame: Day 0 to Progression (approx. 7.5 months) ]
    To evaluate other efficacy measures of IMU-131: duration of objective response (DOR).
  • Change in Tumor Size (Phase 2) [ Time Frame: Day 0 to Progression (approx. 7.5 months) ]
    To evaluate other efficacy measures of IMU-131: change in tumor size (CTS).
  • Humoral and cellular immunogenicity of IMU-131(Phase 2) [ Time Frame: Day 0 to Progression (approx. 7.5 months) ]
    Values and changes from randomization in humoral and cellular immunogenicity data including P467-specific antibodies (IgG), Her-2-specific antibodies (IgG), vaccine-specific cytokine levels and regulatory and effector T and B cells.
  • Incidence of TEAE's (Phase 2) [ Time Frame: Day 0 to Progression (approx. 7.5 months) ]
    Safety will be assessed by comparing the incidence of TEAE's & SAE's in each group.
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures
 (submitted: May 1, 2019)
  • Exploratory Outcome (Phase 1b): Humoral immunogenicity evaluated by P467-specific antibodies (IgG) and Her-2- specific antibodies (IgG) [ Time Frame: Day 0 to Progression (approx. 7.5 months) ]
    Antibodies analysed in serum samples taken across study visits
  • Exploratory Outcome (Phase 1b): Cellular immunogenicity evaluated by vaccine-specific cytokine levels as well as analysis of regulatory and effector T and B cells [ Time Frame: Day 0 to Progression (approx. 7.5 months) ]
    Vaccine-specific cytokine levels and regulatory and effector T and B cells analysed in whole blood samples
  • Exploratory Outcome (Phase 1b): Radiographic data measured by RECIST 1.1 criteria [ Time Frame: Day 0 to Progression (approx. 7.5 months) ]
    Radiographic data will be analyzed descriptively to explore the Response Rate (RR)
  • Exploratory Outcome (Phase 2): Measurement of Serum Prediction Marker of Tumor Progression [ Time Frame: Day 0 to Progression (approx. 7.5 months) ]
    To measure the changes from baseline of serum prediction marker of tumor progression in ng/ml.
  • Exploratory Outcome (Phase 2): Measurement of immunological and biochemical markers [ Time Frame: Day 0 to Progression (approx. 7.5 months) ]
    To measure the changes from baseline of intra-tumor T cells and biochemical markers including CD4+, CD8+ T cells & Treg cells in ng/ml.
Original Other Pre-specified Outcome Measures
 (submitted: June 9, 2016)
  • Exploratory Outcome: Humoral immunogenicity evaluated by P467-specific antibodies (IgG) and Her-2- specific antibodies (IgG) [ Time Frame: Day 0 to Day 56 ]
    Antibodies analysed in serum samples taken across study visits
  • Exploratory Outcome: Cellular immunogenicity evaluated by vaccine-specific cytokine levels as well as analysis of regulatory and effector T and B cells [ Time Frame: Day 0 to Day 56 ]
    Vaccine-specific cytokine levels and regulatory and effector T and B cells analysed in whole blood samples taken at Day 0 and Day 56
  • Exploratory Outcome: Radiographic data measured by RECIST 1.1 criteria [ Time Frame: Day 0 to Day 56 and during Long-term maintenance ]
    Radiographic data will be analyzed descriptively to explore the Response Rate (RR)
 
Descriptive Information
Brief Title  ICMJE A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
Official Title  ICMJE A Phase 1b/2 Open-Label Study With Randomization in Phase 2 of IMU-131 HER2/Neu Peptide Vaccine Plus Standard of Care Chemotherapy in Patients With HER2/Neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction
Brief Summary The Phase 1b study is an open-label, multicenter dose escalation study designed to assess the safety, tolerability, immunogenicity and recommended phase 2 dose (RP2D) of IMU-131. The RP2D will be evaluated in the dose expansion Phase 2 study. The Phase 2 study is a randomized, open label comparison of IMU-131 plus standard of care chemotherapy versus standard of care chemotherapy alone.
Detailed Description

IMU-131 is a single peptide structure composed of 3 individual B-cell epitope peptide sequences selected from HER2/neu structure. Polyclonal antibodies against IMU-131 peptides bind three separate regions of the HER2 receptor and also to the dimerization loop of the HER2 receptor, preventing dimerization, which in turn inhibits intracellular signaling. This blockade of the HER2 signaling pathways is thought to be substantially greater than that with trastuzumab alone. Safety and immunogenicity of the 3 peptides have been shown in Phase 1a testing of an earlier formulation of IMU-131. The shelf stability of the Phase 1a vaccine was not optimal and hence the formulation was adjusted for IMU-131. The three B-cell epitope peptides (P4, P6 and P7) were combined in a specific order resulting in a single fusion peptide of 49 amino acids in length (P467). This new formulation of IMU-131 has extended stability and improved immunogenicity compared to the formulation used previously. The new vaccine IMU-131 produces a stronger and more rapid polyclonal antibody response and is efficient to manufacture compared with previous formulations. Based on these three known epitopes (P4, P6 and P7), the investigators developed a single peptide antigen (P467), which allows simplification of the manufacturing process.

It is hypothesized that administration of IMU-131 in addition to chemotherapy will prolong survival and may delay tumor progression and/or reduce tumor burden in patients with HER2/neu overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma (otherwise known as Advanced Cancer of the Stomach (ASC)).

The Phase 1b study aims to determine the safety and tolerability of IMU-131 and identify the Recommended Phase 2 Dose (RP2D) of IMU-131 in combination with chemotherapy in HER2/neu overexpressing ACS to carry into the Phase 2 dose expansion study. The Phase 2 component will be submitted as an amendment and will be initiated following completion of Phase 1b. Phase 2 will be designed to further characterize the safety and to explore clinical activity of IMU-131 in combination with chemotherapy in HER2/neu overexpressing ACS.The Phase 2 study is a randomized, open label comparison of IMU-131 plus standard of care chemotherapy versus standard of care chemotherapy alone.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Masking Description:
Partially blinded - blinded central review of progression.
Primary Purpose: Treatment
Condition  ICMJE
  • Gastrointestinal Neoplasms
  • Adenocarcinoma
Intervention  ICMJE
  • Biological: IMU-131
    IMU-131 vaccine is a P467-CRM197 peptide antigen in PBS buffer and Montanide ISA 51 Sterile adjuvant
    Other Name: HER-Vaxx
  • Drug: Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.
    Chemotherapy will consist of: cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle), or (in Phase 2 only) oxaliplatin, by intravenous administration at 130 mg/m2 on Day 1 of each cycle and capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle).
    Other Name: Standard of Care Chemotherapy
Study Arms  ICMJE
  • Experimental: Phase 1b
    10, 30, 50μg IMU-131 plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine
    Interventions:
    • Biological: IMU-131
    • Drug: Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.
  • Experimental: Phase 2 - IMU 131 plus chemotherapy
    50 μg IMU-131 plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and Capecitabine.
    Interventions:
    • Biological: IMU-131
    • Drug: Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.
  • Experimental: Phase 2 - Chemotherapy only
    Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and Capecitabine.
    Intervention: Drug: Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 1, 2019)
82
Original Estimated Enrollment  ICMJE
 (submitted: June 9, 2016)
18
Estimated Study Completion Date  ICMJE April 2021
Estimated Primary Completion Date December 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Patient has been informed of the investigational nature of this study and has given written informed consent in accordance with institutional, local, and national guidelines;
  2. Age ≥ 20 years old;
  3. Life expectancy of at least 12 weeks;
  4. Phase 1b: No prior chemotherapy or radiotherapy for advanced gastric or GEJ cancer within 6 months prior to Day 0; Phase 2: No prior chemotherapy or radiotherapy for advanced gastric or GEJ cancer within 3 months prior to Day 0;
  5. Metastatic gastric or GEJ adenocarcinoma, or locally advanced disease not amenable to surgical resection;
  6. HER2/neu overexpression (3+ by immunohistochemistry (IHC) or if IHC 2+ confirmed by fluorescent in situ hybridization [FISH] or chromogenic in situ hybridization [CISH]). Patients with IHC 2+ expression without confirmation of overexpression by fluorescent in situ hybridization [FISH] or chromogenic in situ hybridization [CISH]) may be included in Phase 1b with agreement of Imugene Limited;
  7. Phase 1b: ECOG performance status 0-1; Phase 2: ECOG performance status 0-2;
  8. At least one measurable lesion as defined by RECIST 1.1 criteria. Patients with non-measurable lesions may be included in Phase1b with agreement of Imugene Limited;
  9. Adequate left ventricular ejection function at baseline, defined as LVEF > 50% by echocardiogram or MUGA scan (Multi Gated Acquisition Scan);
  10. Adequate hematologic function: absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelet count ≥ 100 x 109/L, and hemoglobin ≥ 9 g/dL;
  11. Adequate liver function evidenced by bilirubin ≤ 1.5 x laboratory upper limit of normal [ULN], and ALT and AST ≤ 3 x laboratory ULN if no liver involvement or ALT and AST ≤ 5 times laboratory ULN with liver involvement;
  12. Adequate renal function (creatinine ≤ 1.5 x laboratory ULN);
  13. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  14. Male and female patients of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 28 days after the last dose of assigned treatment (see section 4.3 for details). A patient is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active.

Exclusion Criteria:

  1. Previous treatment with trastuzumab or any other HER2/neu targeting antibody or agent;
  2. Continuous systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 4 weeks prior to first dose of study treatment. Inhaled or topical steroids and physiological replacement doses of up to 10 mg daily prednisone equivalents are permitted in the absence of active auto-immune disease;
  3. Prior organ transplant;
  4. Phase 1b: Patient not considered a candidate for 5-FU, capecitabine, or cisplatin chemotherapy; Phase 2: Patient not considered a candidate for 5-FU, capecitabine, cisplatin or oxaliplatin chemotherapy;
  5. History of documented congestive heart failure; angina pectoris requiring antianginal medication; evidence of transmural infarction on ECG; poorly controlled hypertension; clinically significant valvular heart disease; high risk uncontrolled arrhythmias; or New York Heart Association (NYHA) class II heart disease;
  6. If on warfarin (Coumadin®) or other vitamin K antagonists;
  7. Concurrent active malignancy except for adequately controlled limited basal cell carcinoma of the skin;
  8. Peripheral neuropathy or hearing loss of NCI CTCAE Grade > 2;
  9. History of uncontrolled seizures, central nervous disorders or psychiatric disability judged by the investigator to be clinically significant and precluding informed consent, participation in the study, or adversely affecting compliance to study drugs;
  10. Active infection requiring IV antibiotics;
  11. Positive for human immunodeficiency virus (HIV) (HIV 1/2 antibodies) or active hepatitis B (HBsAg reactive) or active hepatitis C (HCV ribonucleic acid [RNA] qualitative) infection;
  12. Pregnant or lactating females;
  13. Major surgery within 4 weeks prior to study entry. Minor surgery (excluding diagnostic biopsy) within 1 week prior to study entry;
  14. Has received a live-virus vaccination within 4 weeks of first study vaccination. Seasonal flu vaccines that do not contain live virus are permitted;
  15. Current or recent (within 4 weeks of first IMU-131 vaccination) treatment with another investigational drug or participation in another investigational study.
  16. Phase 2: Patients with a known diphtheria toxoid hypersensitivity.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 20 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Anthony Good, PhD +61 410 711 329 anthony.good@imugene.com
Listed Location Countries  ICMJE Georgia,   Hong Kong,   India,   Moldova, Republic of,   Serbia,   Taiwan,   Thailand,   Ukraine
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02795988
Other Study ID Numbers  ICMJE IMU.ACS.001
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Imugene Limited
Study Sponsor  ICMJE Imugene Limited
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Mark Marino, MD Imugene Limited
PRS Account Imugene Limited
Verification Date May 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP